Shriram Nallamshetty, MD
Cardiovascular Disease · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
Offices
1 location
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Nallamshetty’s office at (650) 493-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A84801 · Current
Licensed to practise in California · since 2014 · expires 2027-10-31 · Duke University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Money from drug and device companies
$283 in 2023
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Leqvio | $283 | 3 payments
|
See all 3 published payments
| Novartis Pharmaceuticals | Meals · 2023-11-16 | Leqvio | $69 |
| Novartis Pharmaceuticals | Meals · 2023-11-10 | Leqvio | $91 |
| Novartis Pharmaceuticals | Meals · 2023-03-04 | Leqvio | $123 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) · 2023 | Their institution | $136,532 |
| Novartis Pharmaceuticals Corporation · Veterans Affairs (VA) Lipid Optimization Quality Improvement Program (Valor-Qi) in Veterans With Atherosclerotic Cardiovascular Disease (Ascvd) · 2025 | Their institution | $73,643 |
| Novartis Pharmaceuticals Corporation · Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) · 2024 | Their institution | $56,509 |
| Novartis Pharmaceuticals Corporation · Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) · 2025 | Their institution | $50,482 |
| Novartis Pharmaceuticals Corporation · Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) · 2022 | Their institution | $19,427 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients (Victorion-1 Prevent) · 2025 | Their institution | $18,525 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients (Victorion-1 Prevent) · 2024 | Their institution | $13,000 |
| Novartis Pharmaceuticals Corporation · A Randomized, Double-Blind, Placebo-Controlled Multicenter Study To Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients (Victorion-1 Prevent) · 2023 | Their institution | $245 |
Professional record
- NPI
- 1477689131
- Licence
- CA A84801California A84801: Current · expires 2027-10-31
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X); Internal medicine (207R00000X)
- Mailing address
- 3801 Miranda Avenue, Rm B2-124, Building 101, Mail Code 111, Palo Alto, CA, 94304
- NPI first listed
- 2007-02-26
- NPI last updated
- 2024-04-23
- NPI record certified
- 2024-04-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305